351 related articles for article (PubMed ID: 25124532)
1. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
Silverman SL; Komm BS; Mirkin S
Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
[TBL] [Abstract][Full Text] [Related]
2. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
[TBL] [Abstract][Full Text] [Related]
4. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
Borgström F; Ström O; Kleman M; McCloskey E; Johansson H; Odén A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):955-65. PubMed ID: 20532482
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
7. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal Osteoporosis: A Clinical Review.
Watts NB
J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
[TBL] [Abstract][Full Text] [Related]
11. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
[TBL] [Abstract][Full Text] [Related]
12. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?
Miller PD; Derman RJ
Osteoporos Int; 2010 Nov; 21(11):1793-802. PubMed ID: 20309524
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Marques A; Lourenço Ó; Ortsäter G; Borgström F; Kanis JA; da Silva JA
Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
[TBL] [Abstract][Full Text] [Related]
15. New management options for osteoporosis with emphasis on SERMs.
McClung MR
Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
[TBL] [Abstract][Full Text] [Related]
17. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
19. [Osteoporosis in menopausal women between 40 and 65 years old : an algorithm for the gynaecologist].
Surbone A; Vulliemoz N; Gonzalez-Rodriguez E; Chatelain JP; Lamy O
Rev Med Suisse; 2016 Oct; 12(536):1811-1815. PubMed ID: 28692232
[TBL] [Abstract][Full Text] [Related]
20. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
